title: Counterpoint: chemosensitivity assays for recurrent ovarian cancer.
abstract: Unfortunately, no reliable evidence-based data have shown any in vitro chemosensitivity assay strategy to be clinically useful in the management of recurrent ovarian cancer, despite frequent use. Several clinical trials have been proposed with the potential to support or refute the relevance of these approaches.
authors.affiliation: Cancer Treatment Centers of America, Philadelphia, Pennsylvania 19124, USA. maurie.markman@ctca-hope.com
authors.forename: Maurie
authors.initials: M
authors.lastname: Markman
mesh_terms: D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*